News >

Reduced-Dose Cabazitaxel Shows Efficacy in mCRPC

Jason Harris
Published: Friday, Aug 25, 2017

Mario Eisenberger, MD

Mario Eisenberger, MD
Phase III results from the PROSELICA trial showed that 20 mg/m2 of cabazitaxel (Jevtana) was as safe and effective as the 25 mg/m2 dose for postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC). The findings were were published online in the Journal of Clinical Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication